Comparative Pharmacology
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus NAPROXEN.
IBUPROHM COLD AND SINUS vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance.
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%.
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category C
Category D/X
NSAID/Decongestant Combination
NSAID